India stops HCQ research at 22 trial sites
1 min read
India has reported 3,66,946 cases of the novel coronavirus. This includes 1,60,384 active cases, 1,94,324 recoveries and 12,237 deaths. The country has tested 62,49,668 samples.
A day after the World Health Organization (WHO) said hydroxychloroquine was unbeneficial to treat Covid-19 patients, India has decided to discontinue the HCQ arm of the Solidarity Trial at 22 trail sites.
“We have issued instructions about stopping the HCQ arm of the trial to coordinators at trial sites. Howeer, the decision to continue HCQ for patients who have been started on it can be taken by the supervising physician,” said Dr Sheela Godbole, head, Division of Epidemiology, ICMR-National AIDS Research Institute (NARI) and national coordinator of the Solidarity Trial in the country.
In other news, an editorial in the Indian Journal of Medical Research (IJMR) states that not one of the mathematical models predicting India’s coronavirus outbreak “proved correct” as they all “carried a strong bias”.
India has reported 3,66,946 cases of the novel coronavirus. This includes 1,60,384 active cases, 1,94,324 recoveries and 12,237 deaths. The country has tested 62,49,668 samples.
With more than 500 cases Wednesday, Haryana has emerged as a concern as it is the fastest growing state in India’s 10 most affected states. Bihar, on the other hand, offers a glimmer of hope as its cases have slowed down. Once growing very rapidly, the state’s growth rate is now below 3%.
